The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
Morepen Laboratories approves hiving off of medical devices business
According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
India Business grew by 11.9% YoY to Rs. 1196.2 crore
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
